UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported)

May 14, 2007

Trubion Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

Delaware	001-33054	52-2385898
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

2401 Fourth Avenue, Suite 1050
Seattle, Washington

(Address of principal executive offices, including zip code)

(206) 838-0500

(Registrant’s telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o     Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o     Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o     Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o     Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

TABLE OF CONTENTS

Item 2.02. Results of Operations and Financial Condition

Item 9.01. Financial Statements and Exhibits

SIGNATURES

EXHIBIT INDEX

EXHIBIT 99.1

Item 2.02. Results of Operations and Financial Condition.

On May 14, 2007, Trubion Pharmaceuticals, Inc. issued a press release relating to its financial results for the three months ended March 31, 2007. A copy of the press release is furnished herewith as Exhibit 99.1.

This information furnished under “Item 2.02. Results of Operations and Financial Condition,” including the exhibit related thereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be deemed incorporated by reference in any disclosure document of Trubion Pharmaceuticals, Inc., except as shall be expressly set forth by specific reference in such document.

Item 9.01. Financial Statements and Exhibits

(d) Exhibits.

Exhibit No.	Description
99.1	Press Release of Trubion Pharmaceuticals, Inc. issued May 14, 2007

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

TRUBION PHARMACEUTICALS, INC.
By:	/s/ Peter Thompson
	Peter A. Thompson, M.D., FACP
	President, Chief Executive Officer and Chairman of the Board of Directors

Date: May 14, 2007

EXHIBIT INDEX

Exhibit
No.	Description
99.1	Press Release of Trubion Pharmaceuticals, Inc. issued May 14, 2007